Drug intelligence / Profile preview

recombinant human interferon alpha-2 variants

Development stage: Preclinical
Lead developer: Heligenics
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous, Intramuscular, Intravenous, Intralesional

Overview

Recombinant human interferon alpha-2 variants are engineered protein biologics being developed by Heligenics. These variants are designed to optimize the therapeutic profile of native interferon alpha-2 (IFN-α2) by targeting the interferon-alpha receptor (IFNAR). By binding to IFNAR, the drug induces a signaling cascade that promotes antiviral states, inhibits cell proliferation, and modulates immune responses. The program is currently in the lead validation/preclinical stage, with potential applications in treating acute myeloid leukemia, squamous cell carcinoma, polycythemia vera, and hepatitis D.

Other names: Recombinant Human Interferon-α2 VariantsIFN-α2 variantsRecombinant Human Interferon-α2 Variants (Panel A)Recombinant Human Interferon-α2 Variants (Large Panel)

Targets

IFNAR (Immune system modulation via type I interferon receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)

Beyond the preview

Go deeper on recombinant human interferon alpha-2 variants.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant human interferon alpha-2 variants.

Explore the full profile